Abbott data suggests GLP-1 drugs a ‘modest accelerator’ for CGMs: analysts
The analysis of U.S. insurance claims found people on GLP-1 therapy wear their FreeStyle Libre sensors more.
Abbott data suggests GLP-1 drugs a ‘modest accelerator’ for CGMs: analysts Read More »
